Enliven Therapeutics (ELVN) Non-Current Assets (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Non-Current Assets data on file, last reported at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 79.22% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $19.5 million (down 41.44% YoY), and the FY2025 full-year result was $1.3 million, down 83.1% from the prior year.
• Non-Current Assets climbed to $1.7 million in Q1 2026, from $1.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $8.9 million in Q2 2024 to a low of $410000.0 in Q2 2022.
• A 5-year average of $5.5 million and a median of $5.6 million in 2022 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets jumped 1199.02% in 2023 and plunged 83.1% in 2025, its largest moves.
• Tracing ELVN's Non-Current Assets over 5 years: stood at $5.5 million in 2022, then rose by 3.08% to $5.7 million in 2023, then jumped by 33.54% to $7.6 million in 2024, then sank by 83.1% to $1.3 million in 2025, then jumped by 32.95% to $1.7 million in 2026.
• Business Quant data shows ELVN's Non-Current Assets at $1.7 million in Q1 2026, $1.3 million in Q4 2025, and $8.2 million in Q3 2025.